E. Ohman J:or Asset Management’s Denali Therapeutics DNLI Stock Holding History

E. Ohman J:or Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12M	Buy	+160,000	New	+$3.29M	0.1%	109

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E. Ohman J:or Asset Management's DNLI Position: Q2 2026 in Review

E. Ohman J:or Asset Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 160,000 shares worth $4.12M. The stake represents 0.1% of the portfolio and ranks #109 among its holdings.

293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

E. Ohman J:or Asset Management held 160,000 shares of Denali Therapeutics worth $4.12M as of Q2 2026.
Denali Therapeutics was a new E. Ohman J:or Asset Management position in Q2 2026.
Denali Therapeutics made up 0.1% of E. Ohman J:or Asset Management's portfolio in Q2 2026, its #109 holding.
293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2026, filed 10 Jul 2026.